cannabis rescheduling moved forward after an 11-day hearing that closed July 15, 2026, yet opponents compiled detailed evidence that could fuel judicial review. The proceeding tested whether marijuana meets the Controlled Substances Act (CSA) criteria for Schedule III: a currently accepted medical use, lower abuse potential than Schedules I and II, and dependence limited to moderate or low physical or high psychological levels.
Hearing snapshot
– Days of testimony: 11 (concluded July 15, 2026). – Post-hearing briefs due: August 17, 2026 (per Chief ALJ Derek C. Julius). – Key agencies: DEA (decision-maker), HHS (medical-use evaluation under CAMU).
HHS applies a two-part CAMU test: (1) whether marijuana is widely used for medical purposes under implemented state programs and (2) whether at least one such use has credible scientific support. A single qualifying medical use removes marijuana from Schedule I but does not by itself satisfy the CSA’s separate Schedule III requirements on comparative abuse and dependence.
Opponents’ record: what they proved
Opponents of rescheduling focused on multiple vectors of evidence rather than a single legal theory. Their witnesses produced testimony on youth exposure, product variability, diversion, illicit cultivation, and psychiatric risks. Notable contributions:
– Dr. Deepak Cyril D’Souza (Yale): Presented the opposition’s strongest scientific challenge. He cited over 200 peer-reviewed publications, said roughly 30% of users develop cannabis-use disorder, and criticized pain trials HHS relied on for small sample sizes, weak blinding, subjective outcomes, heterogeneous products, and nonstandard dosing. D’Souza described an ongoing randomized, placebo-controlled pain trial of approximately 300 patients intended to address prior limitations.
– Dr. Phillip A. Drum (pharmacist, pro se) and Dr. Karen Randall (emergency physician): Argued state-market products lack pharmaceutical controls—no FDA approval, no standardized dosing, variable labeling and dispensing practices—and described pediatric ingestions, adolescent psychiatric crises, cannabinoid hyperemesis, and cannabis-use disorder cases in acute care.
– Humboldt County Sheriff William F. Honsal: Estimated about 1,500 cultivation sites in his county with roughly 30% illegal; testified to diversion to East Coast markets, organized crime links, environmental damage, and labor exploitation tied to illicit cultivation.
Other witnesses addressed differences among state programs and internal disagreement within agency ranks, including testimony from a DEA pharmacologist subpoenaed by opponents.
What the record did not show
Opponents produced substantial factual material, but the ALJ repeatedly required that evidence be tied to the statutory change before the tribunal—rescheduling to Schedule III. Several gaps mattered:
– Many witnesses described harms tied to state legalization or illicit markets rather than to the direct legal effect of moving marijuana from Schedule I to Schedule III. Rescheduling would keep marijuana federally controlled; it would not legalize unlicensed cultivation or interstate trafficking.
– D’Souza attacked the clinical evidence for pain but did not systematically rebut HHS’s other two indicated uses (anorexia related to a medical condition, and nausea and vomiting) or fully contest HHS’s descriptive finding that one use is widely implemented under state programs.
– Several clinical examples and illustrative graphics introduced by witnesses lacked verifiable provenance; cross-examination exposed internet-sourced images and, in at least one instance, uncertainty about whether an image was AI-generated.
ALJ’s gating questions
Chief ALJ Julius pressed witnesses to match their testimony to the CSA’s statutory definitions. He excluded or discounted testimony that assumed rescheduling would deregulate marijuana or that described outcomes of state legalization or decriminalization rather than the rule under consideration. That line of questioning narrowed which facts could legally affect the scheduling determination.
Government advantage and remaining burdens
HHS and DEA retained a procedural advantage on the core CAMU pathway: HHS’s two-part framework requires only one credible, widespread medical use to remove Schedule I status. Opponents made a credible scientific challenge to the pain evidence, driven chiefly by D’Souza’s critique, but did not comprehensively rebut HHS across all asserted medical uses. Separately, the government still must prove that marijuana’s abuse potential and dependence profile satisfy Schedule III’s comparative requirements.
What may matter on appeal
Opponents assembled a record that highlights omissions and analytic gaps DEA will likely need to address in a final order. The court reviewing any final rule will not substitute policy judgment; it will ask whether DEA applied the statute, considered material evidence (diversion, youth exposure, product variability), and explained how disputed facts affected the three statutory findings. The opposition’s strongest appellate claims will rely on statutory fit, alleged failure to respond to important contradictory evidence, and choice of comparators for abuse liability.
Next steps and timeline
– Post-hearing briefs due: August 17, 2026. These briefs will present legal arguments and tie the factual record to statutory criteria. – Final agency action: DEA must issue a final order following receipt and consideration of briefs; timing will depend on internal agency review and any additional HHS input.
Bottom line
Opponents did not establish that marijuana belongs in Schedule I or II. They did build a detailed administrative record on public-health risks, product variability, youth exposure, diversion, and illicit cultivation that DEA will need to address in a final rule. The case now moves to written briefing and agency decision-making, with appellate risk concentrated on whether DEA adequately explained how the record supports all three Schedule III findings.
